NBIX · Healthcare
NEUROCRINE BIOSCIENCES INC
Smart-money confidence
· 1 of 3 sources firing
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
33
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
◆ Next steps
Interested in NEUROCRINE BIOSCIENCES INC? Here's what to do with it.
◇
Compare with other stocks
Sort 7,111 stocks by confidence, holders, or Congress signal
◈
Backtest the strategy
See how the model has done historically before you commit real money
✉
Get the weekly digest
One email on Sunday · what changed in the model this week
Not financial advice. Bogen Capital surfaces public SEC filings — you decide what to do with them.
Market cap
$17.7B
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Exchange
NasdaqGS
About NEUROCRINE BIOSCIENCES INC
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement…
Who's behind the signal
Every informed buyer we can see on NBIX, across all three feeds.
Hedge funds · 6
AQR Capital Management
Increased +18%
Gotham Asset Mgmt (Greenblatt)
Increased +24%
Bridgewater Associates (Dalio)
Increased +551%
Millennium Management (Englander)
Decreased −55%
Tudor Investment (Paul Tudor Jones)
Decreased −27%
Citadel Advisors
Decreased −90%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Congressional trade history · 3
Every disclosed buy & sell on record — STOCK Act filings
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2021-03-09 | Michael T. McCaul · R-TX | House | BOUGHT | $15,001 - $50,000 |
| 2020-12-21 | Gilbert Ray Cisneros, Jr. · D-CA | House | BOUGHT | $1,001 - $15,000 |
| 2020-07-21 | Gilbert Ray Cisneros, Jr. · D-CA | House | SOLD | $1,001 - $15,000 |
Not a model pick — but on our radar.
NEUROCRINE BIOSCIENCES INC isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
0
New positions
3
Increasing
3
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.2%
Position change
+18%
0.2% of AQR Capital Management's portfolio
Trust weight: 1.1×
% of portfolio
0.1%
Position change
+24%
0.1% of Gotham Asset Mgmt's portfolio
Trust weight: 1.3×
% of portfolio
0.1%
Position change
+551%
0.1% of Bridgewater Associates's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
−55%
0.1% of Millennium Management's portfolio
Trust weight: 1.2×
% of portfolio
0.0%
Position change
−27%
0.0% of Tudor Investment's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−90%
0.0% of Citadel Advisors's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to NEUROCRINE BIOSCIENCES INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell NEUROCRINE BIOSCIENCES INC or any security.
Get the Weekly Update
Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime